Table 3.
JAKi tested for atopic dermatitis.
|
Disease
subtype |
Inhibitor | Target | Administration | Phase | Study number |
|---|---|---|---|---|---|
| AD | Baricitinib | JAK1 JAK2 | Oral | Phase III | NCT03334396 |
| Baricitinib | JAK1 JAK2 | Oral | Phase III | NCT03334422 | |
| Upadacitinib | JAK1 | Oral | Phase II | NCT02925117 | |
| Upadacitinib | JAK1 | Oral | Phase III | NCT03738397 | |
| Upadacitinib | JAK1 | Oral | Phase III | NCT03607422 | |
| Ruxolitinib | JAK1 JAK2 | Oral | Phase II | NCT03011892 | |
| Ruxolitinib | JAK1 JAK2 | Oral | Phase III | NCT03745651 | |
| Delgocitinib | PanJAK | Topical | Phase I | NCT03826901 | |
| Delgocitinib | PanJAK | Topical | Phase II | NCT03725722 | |
| PF-04965842 | JAK1 JAK2 | Oral | Phase III | NCT03796676 | |
| PF-04965842 | JAK1 | Oral | Phase III | NCT03422822 | |
| PF-04965842 | JAK1 | Oral | Phase III | NCT03720470 | |
| PF-04965842 | JAK1 | Oral | Phase III | NCT03627767 | |
| PF-04965842 | JAK1 | Oral | Phase II | NCT02780167 | |
| PF-04965842 | JAK1 | Oral | Phase III | NCT0334960 | |
| PF-04965842 | JAK1 | Oral | Phase III | NCT03575871 | |
| pAD | Upadacitinib | JAK1 | Oral | Phase I | NCT03646604 |
AD, atopic dermatitis; pAD, pediatric atopic dermatitis. Clinical trial program according to clinicaltrials.gov.